血清炎性标志物对非小细胞肺癌免疫治疗的预测价值

doi:10.3760/cma.j.cn371439-20211115-00030

摘要/Abstract

摘要：

免疫检查点抑制剂(ICI)不仅能在短时间内延长非小细胞肺癌(NSCLC)患者的生存时间,甚至还能对肿瘤实现持久应答。然而,ICI的疗效在不同类型NSCLC患者中存在显著异质性,目前仍缺乏普遍的生物标志物来预测ICI治疗的获益情况。炎症在肿瘤的发生发展中起一定作用,血清中多种炎性标志物也成为反映免疫状态的临床指标,如乳酸脱氢酶、C反应蛋白、血清中性粒细胞、淋巴细胞、血小板等指标。这些炎性标志物简单易得,与多种实体肿瘤的预后相关。

关键词: 癌,非小细胞肺, 免疫疗法, 炎性标志物

Abstract:

Immune checkpoint inhibitors (ICIs) can not only prolong the survival time of patients with non-small cell lung cancer (NSCLC) in a short time, but also achieve a lasting response to the tumor. However, there has been significant heterogeneity in the efficacy of ICIs among patients with different types of NSCLC, and there has been still a lack of universal biomarkers to predict the benefit of ICIs treatment. Inflammation has played a definite role in the occurrence and development of tumors, and a variety of inflammatory markers in serum also have become clinical indicators reflecting immune status, such as lactate dehydrogenase, C-reactive protein, serum neutrophils, lymphocytes, platelets and other indicators. These inflammatory markers are easy to obtain and are associated with the prognosis of a variety of solid tumors.

Key words: Carcinoma,non-small-cell lung, Immunotherapy, Inflammatory markers

罗宏, 殷红, 胡广越, 陶红. 血清炎性标志物对非小细胞肺癌免疫治疗的预测价值[J]. 国际肿瘤学杂志, 2022, 49(3): 177-180.

Luo Hong, Yin Hong, Hu Guangyue, Tao Hong. Predictive value of serum inflammatory markers in immunotherapy of non-small cell lung cancer[J]. Journal of International Oncology, 2022, 49(3): 177-180.

参考文献 33

[1]	Global Burden of Disease Cancer Collaboration; Fitzmaurice C, Abate D, et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2017: a systematic analysis for the global burden of disease study[J]. JAMA Oncol, 2019, 5(12):1749-1768. DOI: 10.1001/jamaoncol.2019.2996. doi: 10.1001/jamaoncol.2019.2996 pmid: 31560378
[2]	Joshi S, Durden DL. Combinatorial approach to improve cancer immunotherapy: rational drug design strategy to simultaneously hit multiple targets to kill tumor cells and to activate the immune system[J]. J Oncol, 2019, 2019:5245034. DOI: 10.1155/2019/5245034. doi: 10.1155/2019/5245034
[3]	Mok TSK, Wu YL, Kudaba I, et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial[J]. Lancet, 2019, 393(10183):1819-1830. DOI: 10.1016/S0140-6736(18)32409-7. doi: 10.1016/S0140-6736(18)32409-7
[4]	Wojas-Krawczyk K, Kalinka E, Grenda A, et al. Beyond PD-L1 markers for lung cancer immunotherapy[J]. Int J Mol Sci, 2019, 20(8):1915. DOI: 10.3390/ijms20081915. doi: 10.3390/ijms20081915
[5]	Rossi JF, Lu ZY, Massart C, et al. Dynamic immune/inflammation precision medicine: the good and the bad inflammation in infection and cancer[J]. Front Immunol, 2021, 12:595722. DOI: 10.3389/fimmu.2021.595722. doi: 10.3389/fimmu.2021.595722
[6]	Zhao H, Wu L, Yan G, et al. Inflammation and tumor progression: signaling pathways and targeted intervention[J]. Signal Transduct Target Ther, 2021, 6(1):263. DOI: 10.1038/s41392-021-00658-5. doi: 10.1038/s41392-021-00658-5
[7]	Mishra D, Banerjee D. Lactate dehydrogenases as metabolic links between tumor and stroma in the tumor microenvironment[J]. Cancers (Basel), 2019, 11(6):750. DOI: 10.3390/cancers11060750. doi: 10.3390/cancers11060750
[8]	Deng T, Zhang J, Meng Y, et al. Higher pretreatment lactate dehydrogenase concentration predicts worse overall survival in patients with lung cancer[J]. Medicine (Baltimore), 2018, 97(38):e12524. DOI: 10.1097/MD.0000000000012524. doi: 10.1097/MD.0000000000012524
[9]	Lahoud RM, O'Shea A, El-Mouhayyar C, et al. Tumour markers and their utility in imaging of abdominal and pelvic malignancies[J]. Clin Radiol, 2021, 76(2):99-107. DOI: 10.1016/j.crad.2020.07.033. doi: 10.1016/j.crad.2020.07.033 pmid: 32861463
[10]	Zhang Z, Li Y, Yan X, et al. Pretreatment lactate dehydrogenase may predict outcome of advanced non small-cell lung cancer patients treated with immune checkpoint inhibitors: a meta-analysis[J]. Cancer Med, 2019, 8(4):1467-1473. DOI: 10.1002/cam4.2024. doi: 10.1002/cam4.2024
[11]	Michels N, van Aart C, Morisse J, et al. Chronic inflammation towards cancer incidence: a systematic review and meta-analysis of epidemiological studies[J]. Crit Rev Oncol Hematol, 2021, 157:103177. DOI: 10.1016/j.critrevonc.2020.103177. doi: 10.1016/j.critrevonc.2020.103177
[12]	Iivanainen S, Ahvonen J, Knuuttila A, et al. Elevated CRP levels indicate poor progression-free and overall survival on cancer patients treated with PD-1 inhibitors[J]. ESMO Open, 2019, 4(4):e000531. DOI: 10.1136/esmoopen-2019-000531. doi: 10.1136/esmoopen-2019-000531
[13]	Riedl JM, Barth DA, Brueckl WM, et al. C-reactive protein (CRP) levels in immune checkpoint inhibitor response and progression in advanced non-small cell lung cancer: a bi-center study[J]. Cancers (Basel), 2020, 12(8):2319. DOI: 10.3390/cancers12082319. doi: 10.3390/cancers12082319
[14]	Patil NS, Zou W, Mocci S, et al. C-reactive protein reduction post treatment is associated with improved survival in atezolizumab (anti-PD-L1) treated non-small cell lung cancer patients[J]. PLoS One, 2021, 16(2):e0246486. DOI: 10.1371/journal.pone.0246486. doi: 10.1371/journal.pone.0246486
[15]	Katayama Y, Yamada T, Chihara Y, et al. Significance of inflammatory indexes in atezolizumab monotherapy outcomes in previously treated non-small-cell lung cancer patients[J]. Sci Rep, 2020, 10(1):17495. DOI: 10.1038/s41598-020-74573-0. doi: 10.1038/s41598-020-74573-0 pmid: 33060826
[16]	Lee PY, Oen KQX, Lim GRS, et al. Neutrophil-to-lymphocyte ratio predicts development of immune-related adverse events and outcomes from immune checkpoint blockade: a case-control study[J]. Cancers (Basel), 2021, 13(6):1308. DOI: 10.3390/cancers13061308. doi: 10.3390/cancers13061308
[17]	Li Y, Zhang Z, Hu Y, et al. Pretreatment neutrophil-to-lymphocyte ratio (NLR) may predict the outcomes of advanced non-small-cell lung cancer (NSCLC) patients treated with immune checkpoint inhibitors (ICIs)[J]. Front Oncol, 2020, 10:654. DOI: 10.3389/fonc.2020.00654. doi: 10.3389/fonc.2020.00654
[18]	Russo A, Franchina T, Ricciardi GRR, et al. Baseline neutrophi-lia, derived neutrophil-to-lymphocyte ratio (dNLR), platelet-to-lymphocyte ratio (PLR), and outcome in non small cell lung cancer (NSCLC) treated with nivolumab or docetaxel[J]. J Cell Physiol, 2018, 233(10):6337-6343. DOI: 10.1002/jcp.26609. doi: 10.1002/jcp.26609
[19]	Mezquita L, Preeshagul I, Auclin E, et al. Predicting immunothe-rapy outcomes under therapy in patients with advanced NSCLC using dNLR and its early dynamics[J]. Eur J Cancer, 2021, 151:211-220. DOI: 10.1016/j.ejca.2021.03.011. doi: 10.1016/j.ejca.2021.03.011 pmid: 34022698
[20]	Pavan A, Calvetti L, Dal Maso A, et al. Peripheral blood markers identify risk of immune-related toxicity in advanced non-small cell lung cancer treated with immune-checkpoint inhibitors[J]. Oncologist, 2019, 24(8):1128-1136. DOI: 10.1634/theoncologist.2018-0563. doi: 10.1634/theoncologist.2018-0563
[21]	Ravindranathan D, Master VA, Bilen MA. Inflammatory markers in cancer immunotherapy[J]. Biology (Basel), 2021, 10(4):325. DOI: 10.3390/biology10040325. doi: 10.3390/biology10040325
[22]	Egami S, Kawazoe H, Hashimoto H, et al. Peripheral blood biomarkers predict immune-related adverse events in non-small cell lung cancer patients treated with pembrolizumab: a multicenter retrospective study[J]. J Cancer, 2021, 12(7):2105-2112. DOI: 10.7150/jca.53242. doi: 10.7150/jca.53242
[23]	Bilen MA, Martini DJ, Liu Y, et al. The prognostic and predictive impact of inflammatory biomarkers in patients who have advanced-stage cancer treated with immunotherapy[J]. Cancer, 2019, 125(1):127-134. DOI: 10.1002/cncr.31778. doi: 10.1002/cncr.31778
[24]	Qi Y, Liao D, Fu X, et al. Elevated platelet-to-lymphocyte corresponds with poor outcome in patients with advanced cancer receiving anti-PD-1 therapy[J]. Int Immunopharmacol, 2019, 74:105707. DOI: 10.1016/j.intimp.2019.105707. doi: 10.1016/j.intimp.2019.105707
[25]	Xu H, He A, Liu A, et al. Evaluation of the prognostic role of platelet-lymphocyte ratio in cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis[J]. Int Immunopharmacol, 2019, 77:105957. DOI: 10.1016/j.intimp.2019.105957. doi: 10.1016/j.intimp.2019.105957
[26]	Kartolo A, Holstead R, Khalid S, et al. Serum neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in prognosticating immunotherapy efficacy[J]. Immunotherapy, 2020, 12(11):785-798. DOI: 10.2217/imt-2020-0105. doi: 10.2217/imt-2020-0105 pmid: 32657234
[27]	Benitez JC, Recondo G, Rassy E, et al. The LIPI score and inflammatory biomarkers for selection of patients with solid tumors treated with checkpoint inhibitors[J]. Q J Nucl Med Mol Imaging, 2020, 64(2):162-174. DOI: 10.23736/S1824-4785.20.03250-1. doi: 10.23736/S1824-4785.20.03250-1 pmid: 32107903
[28]	Ruiz-Bañobre J, Areses-Manrique MC, Mosquera-Martínez J, et al. Evaluation of the lung immune prognostic index in advanced non-small cell lung cancer patients under nivolumab monotherapy[J]. Transl Lung Cancer Res, 2019, 8(6):1078-1085. DOI: 10.21037/tlcr.2019.11.07. doi: 10.21037/tlcr.2019.11.07
[29]	Sorich MJ, Rowland A, Karapetis CS, et al. Evaluation of the lung immune prognostic index for prediction of survival and response in patients treated with atezolizumab for NSCLC: pooled analysis of clinical trials[J]. J Thorac Oncol, 2019, 14(8):1440-1446. DOI: 10.1016/j.jtho.2019.04.006. doi: 10.1016/j.jtho.2019.04.006
[30]	Minami S, Ihara S, Komuta K. Pretreatment lung immune prognostic index is a prognostic marker of chemotherapy and epidermal growth factor receptor tyrosine kinase inhibitor[J]. World J Oncol, 2019, 10(1):35-45. DOI: 10.14740/wjon1179. doi: 10.14740/wjon1179 pmid: 30834050
[31]	Petrella F, Radice D, Casiraghi M, et al. Glasgow prognostic score class 2 predicts prolonged intensive care unit stay in patients undergoing pneumonectomy[J]. Ann Thorac Surg, 2016, 102(6):1898-1904. DOI: 10.1016/j.athoracsur.2016.05.111. doi: 10.1016/j.athoracsur.2016.05.111
[32]	Ni XF, Wu J, Ji M, et al. Effect of C-reactive protein/albumin ratio on prognosis in advanced non-small-cell lung cancer[J]. Asia Pac J Clin Oncol, 2018, 14(6):402-409. DOI: 10.1111/ajco.13055. doi: 10.1111/ajco.13055
[33]	Matsubara T, Takamori S, Haratake N, et al. The impact of immune-inflammation-nutritional parameters on the prognosis of non-small cell lung cancer patients treated with atezolizumab[J]. J Thorac Dis, 2020, 12(4):1520-1528. DOI: 10.21037/jtd.2020.02.27. doi: 10.21037/jtd.2020.02.27 pmid: 32395289